A new report launched today shows that global investment into reproductive health products targeted at the developing world was just under US$88m in 2013. The report, Reproductive Health: R&D for the developing world, released by Policy Cures, is the first study of its kind to provide a comprehensive picture of global funding patterns for R&D into reproductive health products in developing countries.
The report, based on a global survey of funding, covers R&D for contraceptives, Multipurpose Prevention Technologies, post-partum haemorrhage, sexually transmitted infections and platform technologies. The majority of funding, $63m, was directed towards R&D for contraceptive products, mostly from US drug companies. All other areas received less than $10m each. No funding was reported for several areas where there was an identified need, including drugs for syphilis and ultra-short acting contraceptive drugs... more
Following claims that US funding cuts have delayed an Ebola vaccine, a new report confirms that the 2013 US budget sequester and pull-outs from the pharmaceutical industry are harming funding to develop drugs and vaccines for other neglected diseases, including tuberculosis (TB), malaria and AIDS.
The seventh annual G-FINDER report, released today, showed that $3.2bn was invested in neglected disease R&D in 2013 – a cut of $193m on the previous year. The US budget sequester was almost entirely responsible for this decrease, with the world’s largest funder, the US National Institutes of Health (US NIH), making a sequester-related cut of $188m (-13%).
“A drop of this size has to be a concern,” said report author Dr Mary Moran, Executive Director of Policy Cures. “Last year the US was fundamental in sustaining global investment levels amidst cuts from other non-US government funders, but we’re simply not seeing that for 2013.”... more
SYDNEY (April 24, 2014) — The first-ever drug regimen to treat both drug-sensitive TB and some forms of multi-drug resistant tuberculosis (MDR-TB) and significantly cut the cost and duration of treatment is about to enter the final stage of clinical trial testing later this year.
“The cost of the new treatment known as PaMZ is anticipated to be around 50-90 dollars instead of the current average cost per patient of 5 to 10 thousand dollars. This is the first modern TB regimen, which could replace our existing TB treatments developed over 50 years ago, and is also the first to be compatible with HIV treatment
“With half of new active TB cases per year in the Asia Pacific region and current therapies unaffordable for most patients in high burden countries PaMZ has the potential to be a game changer for patients and countries in the region,” said Dr Mary Moran, Executive Director of Policy Cures. “And with its dramatically lower cost and shorter treatment times, PaMZ would generate huge savings in Australian aid dollars that are currently spent on expensive, lengthy and increasingly ineffective old TB treatments...” more
The sixth annual G-FINDER survey reports both good and bad news on global investment into research and development (R&D) for new neglected disease products. The good news is that global funding for neglected disease R&D totalled US $3.2 billion in 2012, thanks to an increase in funding from repeat survey participants of $92.1m (up 3.2%) over 2011 levels – a positive change as global investment in neglected disease R&D had been declining since 2009.
But in 2012, non-US government funding fell by $52.6m (down 12.4%), with 11 governments cutting or freezing funding. Since the global financial crisis, total investment from this group has fallen by 20% ($90.6m).... more
Policy Cures today announced that it has received a $5m grant from the Bill & Melinda Gates Foundation to continue its work to improve global health, by supporting increased investment into neglected disease research and development (R&D).
“Policy Cures has conducted the G-FINDER survey supported by the Gates Foundation annually since 2008, providing funders globally with reliable, comprehensive data on the financing of R&D for neglected diseases to inform policy and investment decisions and we’re very pleased to continue our work with the foundation,” said Dr Mary Moran, Executive Director of Policy Cures.
The G-FINDER survey is the most comprehensive report to date on funding of R&D for neglected diseases like malaria, TB, HIV, pneumonia, sleeping sickness and helminth (worm) infections. It covers 31 diseases and 134 product areas for these diseases, including drugs, vaccines, diagnostics, microbicides and vector control products...more
A 5-year review of global neglected disease research & development (R&D) funding shows that, despite increased investment of almost half a billion dollars ($443.7 million) between 2007 and 2011, changing investment patterns – especially from hard-pressed governments - may mean this funding is not always working in favour of development of drugs, vaccines and diagnostics for the world’s poor... more
On September 26th, the German not-for-profit organisation, DSW, launched a specially commissioned report from Policy Cures titled, 'Saving Lives and Creating Impact: EU investment in poverty-related and neglected diseases'. The launch included a breakfast debate and was hosted by Maria da Graça Carvalho, a Member of the European Parliament...read more
A report released by the Global Health Technologies Coalition (GHTC) and Policy Cures finds that the United States government is the largest funder of global health research and development (R&D) in the world, investing $12.7 billion over the past 10 years in the creation of new vaccines, drugs, diagnostics, and other products for neglected diseases of the developing world. That funding, according to the report, helped lead to the development of more than half of the 45 new health products in the last decade that have been used to save lives around the world...read more
BVGH recently published a new report that analyzes drug and vaccine developer engagement in global health. Leveraging data from their Global Health Primer, BVGH explores the extent to which different types of organizations are participating in drug and vaccine development for a broad range of neglected tropical diseases.
A fresh round of funding cuts from rich nations in the wake of the global financial crisis threaten the development of a new generation of lifesaving medicines and vaccines just as they are on the verge of reaching patients in the developing world. Public funding from the world’s richest nations for research and development (R&D) of new neglected disease products fell by US$125m (down 6%) in 2010, according to new data published in the fourth annual G-FINDER report. Diseases like HIV that rely heavily on public funding have been hit the hardest, with a US$70m cut in HIV R&D funding alone... read more
Read the G-FINDER highlights 2011
View the G-FINDER 2011 launch presentation.
"Over the years G-finder has made itself the most relevant tool to acknowledge improvement on innovation. From the perspective of an Institute devoted to Global Health, G-Finder has become a daily tool of reference. Today, however, when economic resources from rich countries are scarce, it becomes not only a reference on innovation, but also a very useful guide for donors and governments to see that the good science to bridge the gap is working, and change is possible."
- Rafael Vilasanjuan, Director, Think Tank, Barcelona Institute for Global Health, IS Global – Barcelona
A new analysis of progress in the global fight against malaria finds a five-fold increase in annual funding for malaria research and development (R&D) in just 16 years—increasing from US$121 million in 1993 to US$612 million in 2009, with a particularly rapid increase since 2004. The funding has generated the strongest pipeline of malaria control and prevention products in history.
The report warns, however, that even a small decline in annual funding could jeopardize this pipeline, derail development of needed products, and paradoxically also increase development costs later... read more
Read the Executive Summary
For the first time the flagship report of the World Health Organization (WHO), known as The World Health Report, will focus on the necessity of research for better health. Decisions regarding healthcare have been and still are being made without a solid grounding in research evidence. In order to reinforce this message that research is critical for meeting health needs and improving outcomes the WHO is collaborating with PLoS Medicine to develop a collection with the title No Health Without Research.
The Policy Cures co-authored article Registering New Drugs for Low Income Countries: The African Challenge was independently selected for inclusion in the WHO/PLoS Collection.